| Non-Small Cell Lung Carcinoma
Krazati vs Mektovi
Side-by-side clinical, coverage, and cost comparison for non-small cell lung carcinoma.Deep comparison between: Krazati vs Mektovi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsMektovi has a higher rate of injection site reactions vs Krazati based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Mektovi but not Krazati, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Krazati
Mektovi
At A Glance
Oral
Twice daily
KRAS G12C inhibitor
Oral
Twice daily
MEK inhibitor
Indications
- Non-Small Cell Lung Carcinoma
- Colorectal Neoplasms
- melanoma
- Non-Small Cell Lung Carcinoma
Dosing
Non-Small Cell Lung Carcinoma 600 mg orally twice daily as a single agent until disease progression or unacceptable toxicity; swallow tablets whole with or without food.
Colorectal Neoplasms 600 mg orally twice daily in combination with cetuximab until disease progression or unacceptable toxicity; swallow tablets whole with or without food.
melanoma 45 mg orally twice daily in combination with encorafenib; reduce to 30 mg orally twice daily for patients with moderate or severe hepatic impairment.
Non-Small Cell Lung Carcinoma 45 mg orally twice daily in combination with encorafenib.
Contraindications
—
—
Adverse Reactions
Most common (>=25%) nausea, diarrhea, vomiting, fatigue, musculoskeletal pain, hepatotoxicity, renal impairment, edema, dyspnea, decreased appetite
Serious pneumonia, dyspnea, renal impairment, sepsis, respiratory failure, pleural effusion, anemia, cardiac failure
Most common (>=25%) fatigue, nausea, diarrhea, vomiting, abdominal pain, musculoskeletal pain, visual impairment, constipation, dyspnea, rash, cough
Serious hemorrhage, diarrhea, anemia, dyspnea, pneumonia, arrhythmia, device related infection, edema, myocardial infarction, pleural effusion
Pharmacology
Adagrasib is an irreversible KRAS G12C inhibitor that covalently binds to the mutant cysteine residue, locking KRAS G12C in its inactive GDP-bound state and preventing downstream signaling without affecting wild-type KRAS.
Binimetinib is a reversible inhibitor of MEK1 and MEK2, upstream regulators of the ERK pathway; combined with encorafenib it targets two different kinases in the RAS/RAF/MEK/ERK pathway for greater anti-proliferative and anti-tumor activity in BRAF mutation-positive tumors.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Krazati
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
Mektovi
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Krazati
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Mektovi
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (0/8)
Humana
Krazati
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Mektovi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Krazati.
$0/fillfill
Mektovi Co-Pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
KrazatiView full Krazati profile
MektoviView full Mektovi profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.